[HTML][HTML] Skp2 is associated with paclitaxel resistance in prostate cancer cells
Y Yang, Y Lu, L Wang, A Mizokami… - Oncology …, 2016 - spandidos-publications.com
Prostate cancer is the most commonly diagnosed tumor in men in the United States. Patients
with hormone-refractory prostate cancer are often treated with paclitaxel, but most of them …
with hormone-refractory prostate cancer are often treated with paclitaxel, but most of them …
[PDF][PDF] Skp2 is associated with paclitaxel resistance in prostate cancer cells
Y YANG, YI LU, L WANG… - ONCOLOGY REPORTS, 2016 - scholar.archive.org
Prostate cancer is the most commonly diagnosed tumor in men in the United States. Patients
with hormonerefractory prostate cancer are often treated with paclitaxel, but most of them …
with hormonerefractory prostate cancer are often treated with paclitaxel, but most of them …
Skp2 is associated with paclitaxel resistance in prostate cancer cells.
Y Yang, Y Lu, L Wang, A Mizokami, ET Keller… - Oncology …, 2016 - europepmc.org
Prostate cancer is the most commonly diagnosed tumor in men in the United States. Patients
with hormone-refractory prostate cancer are often treated with paclitaxel, but most of them …
with hormone-refractory prostate cancer are often treated with paclitaxel, but most of them …
Skp2 is associated with paclitaxel resistance in prostate cancer cells
Y YANG, YI LU, L WANG, A MIZOKAMI… - Oncology …, 2016 - search.proquest.com
Prostate cancer is the most commonly diagnosed tumor in men in the United States. Patients
with hormone-refractory prostate cancer are often treated with paclitaxel, but most of them …
with hormone-refractory prostate cancer are often treated with paclitaxel, but most of them …
Skp2 is associated with paclitaxel resistance in prostate cancer cells
Y Yang, Y Lu, L Wang, A Mizokami, ET Keller… - Oncology …, 2016 - go.gale.com
Prostate cancer is the most commonly diagnosed tumor in men in the United States. Patients
with hormonerefractory prostate cancer are often treated with paclitaxel, but most of them …
with hormonerefractory prostate cancer are often treated with paclitaxel, but most of them …
Skp2 is associated with paclitaxel resistance in prostate cancer cells
Y Yang, Y Lu, L Wang, A Mizokami… - Oncology …, 2016 - pubmed.ncbi.nlm.nih.gov
Prostate cancer is the most commonly diagnosed tumor in men in the United States. Patients
with hormone-refractory prostate cancer are often treated with paclitaxel, but most of them …
with hormone-refractory prostate cancer are often treated with paclitaxel, but most of them …
[PDF][PDF] Skp2 is associated with paclitaxel resistance in prostate cancer cells
Y YANG, YI LU, L WANG, A MIzOKAMI - ONCOLOGY REPORTS, 2016 - researchgate.net
Prostate cancer is the most commonly diagnosed tumor in men in the United States. Patients
with hormonerefractory prostate cancer are often treated with paclitaxel, but most of them …
with hormonerefractory prostate cancer are often treated with paclitaxel, but most of them …
[HTML][HTML] Skp2 is associated with paclitaxel resistance in prostate cancer cells
Y Yang, Y Lu, L Wang, A Mizokami… - Oncology …, 2016 - spandidos-publications.com
Prostate cancer is the most commonly diagnosed tumor in men in the United States. Patients
with hormone-refractory prostate cancer are often treated with paclitaxel, but most of them …
with hormone-refractory prostate cancer are often treated with paclitaxel, but most of them …
Skp2 is associated with paclitaxel resistance in prostate cancer cells
Y YANG, YI LU, L WANG… - ONCOLOGY REPORTS, 2016 - ingentaconnect.com
Prostate cancer is the most commonly diagnosed tumor in men in the United States. Patients
with hormone-refractory prostate cancer are often treated with paclitaxel, but most of them …
with hormone-refractory prostate cancer are often treated with paclitaxel, but most of them …
[引用][C] Skp2 is associated with paclitaxel resistance in prostate cancer cells
Y YANG, YI LU, L WANG, A MIZOKAMI, ET KELLER… - Oncology …, 2016 - cir.nii.ac.jp